Skip to main content
SpringerLink
Log in

The Regulation of FasL Expression—A Distinguishing Feature Between Monocytes and T Lymphocytes/NK Cells with Possible Implications for SLE

  • Published:
Journal of Clinical Immunology Aims and scope Submit manuscript

Abstract

Monocytes and lymphocytes from patients with systemic lupus erythematosus (SLE) had a higher cell surface expression of FasL than the corresponding cells from healthy individuals. Inhibitors of metalloproteases upregulated the surface expression of FasL in peripheral blood lymphocytes (PBL), indicating that a metalloprotease is responsible for the cleavage of FasL. The level of sFasL in serum was slightly increased in the patient group compared to the controls. Therefore, the possible contribution of various mononuclear cell types to the release of FasL was analyzed. Isolated NK cells and T lymphocytes released FasL into the medium and the release was prevented by inhibitors of metalloproteases. In contrast, isolated monocytes did not release FasL. FasR expression was elevated in patients with inverted CD4/CD8 ratio, while FasL expression showed no relationship to CD4/CD8 ratio. The absence of FasL release by isolated cells and a high level of surface expression of FasL distinguish monocytes and T lymphocytes/NK cells.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. Scaffidi C, Kirchhoff S, Krammer PH, Peter ME: Apoptosis signaling in lymphocytes. Curr Opin Immunol 11:277-285, 1999

    Google Scholar 

  2. McNally J, Yoo DH, Drappa J, Chu JL, Yagita H, Friedman SM, Elkon KB: Fas ligand expression and function in systemic lupus erythematosus. J. Immunol 159:4628-4636, 1997

    Google Scholar 

  3. Lynch DH, Ramsdell F, Alderson MR: Fas and FasL in the homeostatic regulation of immune responses. Immunol. Today 16:569-574, 1995

    Google Scholar 

  4. Rathmell JC, Cooke MP, Ho W, Gein J, Townsend SE, Davis MM, Goodnow CC: CD95 (Fas)-dependent elimination of self-reactive B cells upon interaction with CD4+ T cells. Nature 376:181-184, 1995

    Google Scholar 

  5. Rathmell JC, Townsend SE, Xu JC, Flavell RA, Goodnow CC: Expansion or elimination of B cells in vivo: dual role for CD40-and Fas (CD95)-ligands modulated by the B cell antigen receptor. Cell 57:319-329, 1996

    Google Scholar 

  6. Nagata S: Fas and Fas ligand: A death factor and its receptor. Adv Immunol 57:129-144, 1994

    Google Scholar 

  7. Leithaüser F, Dhein J, Mechtersheimer G, Koretz K, Bruderlein S, Henne C, Schmidt A, Debatin KM, Krammer PH, Möller P: Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest 69:415-429, 1993

    Google Scholar 

  8. Suda T, Okazaki T, Naito Y, Yokota T, Arai N, Ozaki S, Nakao K, Nagata S: Expression of the Fas ligand in the cells of T cell lineage. J Immunol 154:3806-3813, 1995

    Google Scholar 

  9. Montel AH, Bochan MR, Hobbs JA, Lynch DH, Brahmi Z: Fas involment in cytotoxicity mediated by human NK cells. Cell Immunol 166:236-246, 1995

    Google Scholar 

  10. Tanaka M, Itai T, Adachi M, Nagata S: Downregulation of Fas ligand by shedding. Nature Med 4:31-36, 1998

    Google Scholar 

  11. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke RC: A role for CD95 ligand in preventing graft rejection. Nature 377:630-632, 1995

    Google Scholar 

  12. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA: Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270:1189-1192, 1995

    Google Scholar 

  13. Cohen PL, Eisenberg RA: The lpr and gld genes in systemic autoimmunity: life and death in the Fas lane. Immunol Today 13:427-428, 1992

    Google Scholar 

  14. Nagata S, Suda T: Fas and Fas ligand: lpr and gld mutations. Immunol Today 16:39-43, 1995

    Google Scholar 

  15. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S: Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356:314-317, 1992

    Google Scholar 

  16. Emlen W, Niebur J, Kadera R: Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. J Immunol 152:3685-3692, 1994

    Google Scholar 

  17. Utz PJ, Hottelet, Schur PH, Anderson P: Proteins phosphorylated during stress-induced apoptosis are common targets for autoantibody production in patients with systemic lupus erythematosus. J Exp Med 185:843-854, 1997

    Google Scholar 

  18. Fisher GH, Rosenberg FJ, Straus SE, Dale JK, Middelton LA, Lin AY, Strober W, Lenardo MJ, Puck JM: Dominant interfering Fas gene mutations impair apoptosis in a human lymphoproliferative syndrome. Cell 81:935-946, 1995

    Google Scholar 

  19. Drappa J, Vaishnaw AK, Sullivan KE, Chu JL, Elkon KB: Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity. N Engl J Med 335:1643-1649, 1996

    Google Scholar 

  20. Rieux-Laucat F, Le Deist F, Hivroz, Roberts IAG, Debatin KM, Fischer A, de Villartay JP: Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 268: 1347-1349, 1995

    Google Scholar 

  21. Mysler E, Bini P, Drappa J, Ramos P, Friedman SM, Krammer PH, Elkon KB: The APO-1/Fas protein in human systemic lupus erythematosus. J Clin Invest 93:1029-1034, 1994

    Google Scholar 

  22. Mariani SM, Matiba B, Baümler C, Krammer PH: Regulation of cell surface APO-1/Fas (CD95) ligand expression by metalloproteases. Eur J Immunol 25:2303-2307, 1995

    Google Scholar 

  23. Cascino I, Fiucci G, Papoff G, Ruberti G: Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J Immunol 154:2706-2713, 1995

    Google Scholar 

  24. Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, Barr PJ, Mountz JD: Protection from Fas mediated apoptosis by a soluble form of the Fas molecule. Science 263:1759-1762, 1994

    Google Scholar 

  25. Suda T, Hashimoto H, Tanaka M, Ochi T, Nagata S: Membrane Fas ligand kills human pheripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J Exp Med 186:2045-2050, 1997

    Google Scholar 

  26. Nozawa K, Kayagaki N, Tokano Y, Yagita H, Okumura K, Hasimoto H: Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases. Arth Rheum 40:1126-1129, 1997

    Google Scholar 

  27. Tanaka M, Suda T, Takahashi T, Nagata S: Expression of the functional soluble form of human Fas ligand in activated lymphocytes. EMBO J 14:1129-1135, 1995

    Google Scholar 

  28. Kayagaki N, Kawasaki A, Ebata T, Ohmoto H, Ikeda S, Inoue S, Yoshino K, Okumura K, Yagita H: Metalloproteinase-mediated release of human Fas ligand. J Exp Med 182:1777-1783, 1995

    Google Scholar 

  29. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arth Rheum 25:1271-1277, 1982

    Google Scholar 

  30. Hochberg MC: Updating the American College of Rheumatology revised criteria for classification of systemic lupus erythematosus. Arth Rheum 40:1725, 1997

    Google Scholar 

  31. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH: Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis studies in SLE. Arth Rheum 35:630-640, 1992

    Google Scholar 

  32. Gladman DD, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, Bacon P, Bombardieri S, Hanly J, Hay E, Isenberg D, Jones J, Kalunian K, Maddison P, Nived O, Petri M, Richter M, Sanches-Guerrero J, Snaith M, Sturfelt G, Symmons D, Zoma A: The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arth Rheum 39:363-369, 1996

    Google Scholar 

  33. Chomczynski P, Sacchi N: Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 152:156-159, 1987

    Google Scholar 

  34. Galon J, Moldovan I, Galinha A, Provost-Marloie MA, Kaudewitz H, Roman-Roman S, Fridman WH, Sautes C: Identification of the cleavage site involved in production of plasma soluble Fc gamma receptor type III (CD16). Eur J Immunol 28:2101-2107, 1998

    Google Scholar 

  35. Gearing AJH, Beckett P, Christodoulou M, Churchill M, Clements J, Davidson AH, Drummond AH, Galloway WA, Gilbert R, Gordon JL, Leber TM, Mangan M, Miller K, Nayee P, Owen K, Patel S, Thomas W, Wells G, Wood LM, Woolley K: Processing of tumor necrosis factor-aprecursor by metalloproteinases. Nature 370:555-557, 1994

    Google Scholar 

  36. Brown SB, Savill J: Phagocytosis triggers macrophage release of Fas ligand and induces apoptosis of bystander leukocytes. J Immunol 162:480-485, 1999

    Google Scholar 

  37. Heidenreich S: Monocyte CD14: A multifunctional receptor engaged in apoptosis from both sides. J Leukoc Biol 65:737-743, 1999

    Google Scholar 

  38. Birkedal-Hansen H, Moore WGI, Bodden MK, Windsor LJ, Birkedal-Hansen B, DeCarlo A, Engler JA: Matrix metalloproteinases: A review. Crit Rev Oral Biol Med 4:197-250, 1993

    Google Scholar 

  39. Mitsiades N, Poulaki V, Kotoula V, Leone A, Tsokos M: Fas ligand is present in tumors of the Ewing's sarcoma family and is cleaved into a soluble form by a metalloproteinase. Am J Pathol 153:1947-1956, 1998

    Google Scholar 

  40. Powell WC, Fingleton B, Wilson CL, Boothby M, Matrisian LM: The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis. Curr Biol 9:1441-1447, 1999

    Google Scholar 

  41. Hill GE: Cardiopulmonary bypass-induced inflamation: Is it important? J Cardiothorac Vasc Anesth 12:21-25, 1998

    Google Scholar 

  42. Kiener PA, Davis PM, Starling GC, Mehlin C, Klebanoff SJ, Ledbetter JA, Liles WC: Differential induction of apoptosis by Fas-Fas ligand interactions in human monocytes and macrophages. J Exp Med 185:1511-1516, 1997

    Google Scholar 

  43. Kiener PA, Davis PM, Rankin BM, Klebanoff SJ, Ledbetter JA, Starling GC, Liles WC: Human monocytic cells contain high levels of intracellular Fas ligand: rapid release following cellular activation. J Immunol 159:1594-1598, 1997

    Google Scholar 

  44. Verneris MR, Kornacker M, Mailander V, Negrin RS: Resistance of ex vivo expanded CD3+CD56+ T cells to Fas-mediated apoptosis. Cancer Immunol Immunother 49:335-345, 2000

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Immunology, Umeå University, S-90185, Umeå, Sweden

    Kjell Eneslãtt & Karl-gõsta Sundqvist

  2. Department of Rheumatology, University Hospital, Umeå, Sweden

    Solbritt Rantapãã-Dahlqvist & Agneta Uddhammar

Authors
  1. Kjell Eneslãtt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Solbritt Rantapãã-Dahlqvist
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Agneta Uddhammar
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Karl-gõsta Sundqvist
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Eneslãtt, K., Rantapãã-Dahlqvist, S., Uddhammar, A. et al. The Regulation of FasL Expression—A Distinguishing Feature Between Monocytes and T Lymphocytes/NK Cells with Possible Implications for SLE. J Clin Immunol 21, 183–192 (2001). https://doi.org/10.1023/A:1011035115342

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1011035115342

Search

Navigation